Outlook Therapeutics (OTLK) vs Yarrow Bioscience (YARW)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Yarrow Bioscience (YARW) has outperformed Outlook Therapeutics (OTLK) over the past year, losing 4.6% versus a loss of 51.3%. Over five years, YARW leads with a -98.2% price change compared with -98.6% for OTLK. Yarrow Bioscience is the larger company by market cap ($183.4 million vs $145.8 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | OTLK | YARW |
|---|---|---|
| Share price | $0.5989 | $19.71 |
| Market cap | $145.80M | $183.39M |
| 1-day change | +6.19% | -0.81% |
| YTD return | -62.09% | -32.03% |
| 1-year return | -51.31% | -4.55% |
| 5-year return | -98.58% | -98.20% |
| EPS (TTM) | $-0.74 | — |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.54 | $46.95 |
| 52-week low | $0.161 | $16.05 |
| Distance from 52-week high | -76.40% | -58.02% |
| Analyst consensus | none | none |
| Avg. price target upside | +739.87% | +189.19% |
| Average volume | 13.43M | 85.28K |
| Shares outstanding | 243.45M | 9.30M |
| Employees | 17 | 7 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- YARW has outperformed OTLK by 46.8 percentage points over the past year.
About Outlook Therapeutics
OTLK stock →Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.
Healthcare · Biotechnology · 17 employees
About Yarrow Bioscience
YARW stock →Yarrow Bioscience, Inc. operates as a clinical-stage biotechnology company that engages in developing transformative therapies for autoimmune thyroid diseases.
Healthcare · Biotechnology · 7 employees
OTLK vs YARW FAQ
Which is bigger, Outlook Therapeutics or Yarrow Bioscience?
Yarrow Bioscience (YARW) is larger, with a market capitalization of $183.39M compared with $145.80M for Outlook Therapeutics (OTLK).
Which stock has performed better over the past year, OTLK or YARW?
YARW returned -4.55% over the past 12 months, compared with -51.31% for OTLK (price return, excluding dividends). Past performance does not predict future results.
Are Outlook Therapeutics and Yarrow Bioscience in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.